Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)
Forecasted
NIH funds testing centers to evaluate the safety and efficacy of somatic cell genome editing for human disease therapies using preclinical models; clinical trials are not allowed.
Browse similar grants
Funder: National Institutes of Health
Due Dates (Anticipated): January 2028 (Application deadline)
Funding Amounts: $580,000–$900,000 per award; 3 awards expected
Summary: Supports testing centers that evaluate the efficacy and safety of somatic cell genome editing technologies for translational applications.
Key Information: Clinical trials are not allowed under this U42 cooperative agreement.
Description
The National Institutes of Health supports testing centers that provide resources and testing services for somatic cell genome editing technologies and their preclinical development as therapeutics for human diseases. Centers will work with NIH-funded investigators to assess genome editing and delivery technologies, determine disease-specific editing thresholds with minimal off-target effects, and establish feasibility in model systems. The program particularly emphasizes new approach methodologies (NAMs) that complement traditional in vivo models.
Centers will establish in vivo and in vitro models, including human-biology-based models, and develop assays and standard operating procedures for evaluating editing technologies. Although each center will address a limited number of focused projects, its pipelines and adaptable core models are expected to support broader biomedical research. The goal is to improve optimization, scientific rigor, transparency, and experimental reproducibility.
